New Delhi | Jagran News Desk: With the world still battling the coronavirus pandemic while pinning its hope on a vaccine for the disease, the chief executive of the world’s largest vaccine manufacturing firm has said that sufficient production of COVID-19 vaccine to meet the global requirements will not be met until the end of 2024.

In an interview with Financial Times, Adar Poonawalla, chief executive of Serum Institute on India, said that pharma firms were not increasing production capacity to meet the global requirements of vaccine in lesser duration.

“It’s going to take four to five years until everyone gets the vaccine on this planet,” Poonawalla was quoted as saying.


The SII chief executive had earlier predicted that if coronavirus shot is a two-dose vaccine, as in the case of measles or rotavirus, then at least 15 billion doses will be required globally. 

Pune-based SII has partnered with five international pharmaceutical companies, including AAstraZeneca and Novavax, to develop a vaccine for the virus. The firm has pledged to produce 1 billion doses and has promised 50 per cent of them for India. 

Last week, the SII said that it will restart clinical trials of AstraZeneca's COVID-19 vaccine candidate after getting the permission from the Drugs Controller General of India (DCGI). 

Earlier, AstraZeneca said that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that the trials were safe.

AstraZeneca's COVID-19 vaccine candidate is one of the nine in the world currently in Phase III human trials. The AZD1222 vaccine uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the Covid-19 coronavirus uses to invade cells.

(Note: Jagran English has not verified the statement with the company or the spokesman and does not vouch for its accuracy.)     

Posted By: Abhinav Gupta